Preterm Premature Rupture of Membranes: Perspectives Surrounding Controversies in Management

Kjersti M. Aagaard-Tillery; Francis S. Nuthalapaty; Patrick S. Ramsey; Kirk D. Ramin

doi:10.1055/s-2005-870659

American Journal of Perinatology, Table of Contents

Am J Perinatol 2005; 22(6): 287-297
DOI: 10.1055/s-2005-870659

REVIEW ARTICLE

Preterm Premature Rupture of Membranes: Perspectives Surrounding Controversies in Management

Kjersti M. Aagaard-Tillery¹ , Francis S. Nuthalapaty² , Patrick S. Ramsey² , Kirk D. Ramin³

¹Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Utah Health Sciences, Salt Lake City, Utah
²Division of Maternal-Fetal Medicine, Center for Research in Women’s Health, University of Alabama at Birmingham, Birmingham, Alabama
³Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Minnesota, Minneapolis, Minnesota

Abstract

ABSTRACT

Preterm premature rupture of the membranes (PPROM) occurs in approximately 3% of all pregnancies, and accounts for one third of all preterm births. Despite its prevalence, optimal management of PPROM remains largely undefined and lacks conformity. In this article, we review the pathophysiology of PPROM, and summarize the available literature describing various management strategies in an effort to define current controversies in the management of PPROM.

KEYWORDS

Preterm premature rupture of membranes - prematurity - pregnancy

Full Text

References

REFERENCES

1 Mercer B M. Preterm premature rupture of the membranes. Obstet Gynecol. 2003; 101 178-193
2 American College of Obstetricians and Gynecologists Practice Bulletin .Premature Rupture of Membranes. Washington, DC; American College of Obstetricians and Gynecologists June 1998 No. 1
3 Garite T J. Management of premature rupture of membranes. Clin Perinatol. 2001; 28 837-844
4 Parry S, Strauss J F. Mechanisms of disease: premature rupture of the fetal membranes. N Engl J Med. 1998; 338 663-670
5 Meis P J, Ernest J M, Moore M L. Causes of low birth weight births in public and private patients. Am J Obstet Gynecol. 1987; 156 1165-1168
6 Goldenberg R L. The management of preterm labor. Obstet Gynecol. 2002; 100 1020-1037
7 Garite T J. Premature rupture of the membranes: the enigma of the obstetrician. Am J Obstet Gynecol. 1985; 151 1001-1005
8 Graham R L, Gilstrap III L C, Hauth J C et al.. Conservative management of patients with premature rupture of fetal membranes. Obstet Gynecol. 1982; 59 607-611
9 Capeless E L, Mead P B. Management of preterm premature rupture of membranes: lack of a national consensus. Am J Obstet Gynecol. 1987; 157 11-12
10 Cox S M, Williams M L, Leveno K J. The natural history of preterm ruptured membranes: what to expect of expectant management. Obstet Gynecol. 1988; 71 558-562
11 Schmidt W. The amniotic fluid compartment: the fetal habitat. Adv Anat Embryol Cell Biol. 1992; 127 1-100
12 Arias F, Gonzalez-Ruiz A R, Jacobson R L. Recent advances in the pathophysiology and management of preterm premature rupture of the fetal membranes. Curr Opin Obstet Gynecol. 1999; 11 141-147
13 Casey M L, MacDonald P C. Interstitial collagen synthesis and processing in human amnion: a property of the mesenchymal cell. Biol Reprod. 1996; 55 1253-1256
14 Malak T M, Ockleford C D, Bell S C et al.. Confocal immunofluorescence localization of collagen types I, III, IV, V and VI and their ultrastructural organization in term human fetal membranes. Placenta. 1993; 14 385-406
15 Casey M L, McDonald P C. Interstitial collagen synthesis and processing in human amnion: a property of the mesenchymal cells. Biol Reprod. 1996; 55 1253-1260
16 Fortunato S J, Menon R. Screening of novel matrix metalloproteinases (MMPs) in human fetal membranes. J Assist Reprod Genet. 2002; 19 483-486
17 Ferrand P E, Parry S, Sammel M et al.. A polymorphism in the matrix metalloproteinase-9 promoter is associated with increased risk of preterm premature rupture of membranes in African Americans. Mol Hum Reprod. 2002; 8 494-501
18 Fujimoto T, Parry S, Urbanek M et al.. A single nucleotide polymorphism in the matrix metalloproteinase-1 (MMP-1) promoter influences amnion cell MMP-1 expression and risk for preterm premature rupture of the fetal membranes. J Biol Chem. 2002; 277 6296-6302
19 Woods Jr J R, Plessinger M, Miller R K. Vitamins C and E: missing links in preventing preterm premature rupture of membranes?. Am J Obstet Gynecol. 2001; 185 5-10
20 McGregor J A, Lawellin D, Franco-Buff A, Todd J K, Makowski E L. Protease production by microorganisms associated with reproductive tract infection. Am J Obstet Gynecol. 1986; 154 109-114
21 Hillier S L, Martius J, Krohn M A, Kiviat N, Holmes K K, Eschenbach D A. A case-controlled study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med. 1988; 319 972-978
22 Glasson J H, Woods W H. Immunoglobulin proteases in bacteria associated with bacterial vaginosis. Aust J Med Lab Sci. 1988; 9 63-65
23 McGregor J A, French J I, Jones W et al.. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol. 1994; 170 1048-1060
24 Katsura M, Ito A, Hirakawa S, Mori Y. Human recombinant interleukin 1 (alpha) increases biosynthesis of collagenase and hyaluronic acid in cultured human chorionic cells. FEBS Lett. 1989; 244 315-318
25 So T, Ito A, Sato T, Mori Y, Hirakawa S. Tumor necrosis factor-(alpha) stimulates the biosynthesis of matrix metalloproteinases and plasminogen activator in cultured human chorionic cells. Biol Reprod. 1992; 46 772-778
26 Tjugum J, Norstrom A. The influence of prostaglandin E2 and oxytocin on the incorporation of [3H]proline and [3H]glucosamine in the human amnion. Eur J Obstet Gynecol Reprod Biol. 1985; 19 137-143
27 DiBattista J A, Pelltier J P, Zafarullah M, Fujimoto N, Obata K, Martel-Pelletier J. Coordinate regulation of matrix metalloproteinases and tissue inhibitor of metalloproteinase expression in human synovial fibroblasts. J Rheumatol Suppl. 1995; 43 123-128
28 Guller S, Kong L, Wozniak R, Lockwood C J. Reduction of extracellular matrix protein expression in human amnion epithelial cells by glucocorticoids: a potential role in preterm rupture of the fetal membranes. J Clin Endocrinol Metab. 1995; 80 2244-2250
29 McLaren J, Taylor D J, Bell S C. Increased incidence of apoptosis in non-labor affected cytotrophoblast cells in term fetal membranes overlying the cervix: implications for preterm birth. Hum Reprod. 1999; 14 2895-2900
30 Allen S. Tocolytic therapy in preterm PROM. Clin Obstet Gynecol. 1998; 41 842-848
31 Johnson J W, Daikoku N H, Niebyl J R et al.. Premature rupture of membranes and prolonged latency. Obstet Gynecol. 1981; 57 547-556
32 Lewis D F, Major C A, Towers C V, Asrat T, Harding J A, Garite T J. Effects of digital vaginal examinations on latency period in preterm premature rupture of membranes. Obstet Gynecol. 1992; 80 630-634
33 Alexander J M, Mercer B M, Miodovnik M et al.. The impact of digital cervical examination on expectantly managed preterm rupture of membranes. Am J Obstet Gynecol. 2000; 183 1003-1007
34 Fanaroff A A, Wright L L, Stevenson D K et al.. Very-low-birth-weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, May 1991-1992. Am J Obstet Gynecol. 1995; 173 1423-1431
35 McGregor J A, French J I, Seo K. Antimicrobial therapy in preterm premature rupture of membranes: results of a prospective, double-blind, placebo-controlled trial of erythromycin. Am J Obstet Gynecol. 1991; 165 632-640
36 Mercer B M, Arhheart K L. Antimicrobial therapy in expectant management of preterm premature rupture of the membranes. Lancet. 1995; 346 1271-1279
37 Mercer B M, Miodovnik M, Thurnau G R et al.. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. JAMA. 1997; 278 989-995
38 Kenyon S L, Taylor D J, Tarnow-Mordi W et al.. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomized trial. Lancet. 2001; 357 979-988
39 Leveno K J, Cox K, Roark M L. Cervical dilatation and prematurity revisited. Obstet Gynecol. 1986; 68 434-435
40 National Institutes of Health Consensus Development Panel .Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH publication No. 95-3784. Bethesda, MD; National Institute of Child Health and Human Development November 1994
41 Garite T J, Keegan K A, Freeman R K, Nageotte M P. A randomized trial of ritodrine tocolysis versus expectant management in patients with premature rupture of membranes at 25 to 30 weeks of gestation. Am J Obstet Gynecol. 1987; 157 388-393
42 Weiner C P, Renk K, Klugman M. The therapeutic efficacy and cost effectiveness of aggressive tocolysis for premature labor associated with premature rupture of the membranes. Am J Obstet Gynecol. 1988; 159 216-222
43 Mercer B M, Crocker L G, Boe N M, Sibai B M. Induction versus expectant management in premature rupture of the membranes with mature amniotic fluid at 32 to 36 weeks: a randomized trial. Am J Obstet Gynecol. 1993; 169 775-782
44 Cox S M, Leveno K J. Intentional delivery versus expectant management with preterm ruptured membranes at 30-34 weeks gestation. Obstet Gynecol. 1995; 86 875-879
45 Naef R W, Albert J R, Ross E L, Weber B M, Martin R W, Morrison J C. Premature rupture of membranes at 34 to 37 weeks gestation: aggressive versus conservative management. Am J Obstet Gynecol. 1998; 178 126-130
46 Mercer B M, Goldenberg R L, Moawad A H et al.. The Preterm Prediction Study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. Am J Obstet Gynecol. 1999; 181 1216-1221
47 Ramsey P S, Nuthalapaty F S, Lu G, Ramin S, Nuthalapaty E S, Ramin K D. Contemporary management of preterm premature rupture of membranes (PPROM): a survey of maternal-fetal medicine providers. Am J Obstet Gynecol. 2004; 191 1497-1502
48 Nuthalapaty F S, Ramsey P S, Lu G, Ramin S M, Nuthalapaty E S, Ramin K D. Contemporary management of PPROM: does practice setting make a difference?. Am JObstet Gynecol. 2003; 198 S176
49 Yoon B H, Jun J K, Romero R et al.. Amniotic fluid inflammatory cytokines (interleukin 6, interleukin 1B, and tumor necrosis factorα), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol. 1997; 177 19-26
50 Yoon B H, Romero R, Park J S, Kim C J, Choi J H, Han T R. Fetal exposure to an intra-amniotic inflammation and the development of cerebral palsy at the age of three years. Am J Obstet Gynecol. 2000; 182 675-681
51 Vigneswaran R. Infection and preterm birth: evidence of a common causal relationship with bronchopulmonary dysplasia and cerebral palsy. J Paediatr Child Health. 2000; 36 293-296
52 Nelson K B, Ellenberg J H. Antecedents of cerebral palsy: multivariate analysis of risk. N Engl J Med. 1986; 315 81-86
53 Gaudet L M, Smith G N. Cerebral palsy and chorioamnionitis: the inflammatory cytokine link. Obstet Gynecol Surv. 2001; 56 433-436
54 Wu Y W, Colford Jr J M. Chorioamnionitis as a risk factor for cerebral palsy: a meta-analysis. JAMA. 2000; 284 1417-1424
55 Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev. 2000; 2 , CD000065
56 Crowley P A. Antenatal corticosteroid therapy: a meta-analysis of randomized trials, 1972 to 1994. Am J Obstet Gynecol. 1995; 173 322-335
57 Morales W J, Diebel D, Lazar A J, Zadrozny D. The effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome in preterm gestations with premature rupture of membranes. Am J Obstet Gynecol. 1986; 154 591-595
58 Effect of corticosteroids for fetal maturatin on perinatal outcomes. NIH Consens Statement. 1994; 12 1-24
59 Gardner M O, Papile L A, Wright L L. Antenatal corticosteroids in pregnancies complicated by preterm premature rupture of membranes. Obstet Gynecol. 1997; 90 851-853
60 Imseis H M, Iams J D. Glucocorticoid use in patients with preterm premature rupture of the fetal membranes. Semin Perinatol. 1996; 20 439-450
61 Vermillion S T, Soper D E, Bland M L, Newman R B. Effectiveness of antenatal corticosteroid administration after preterm premature rupture of the membranes. Am J Obstet Gynecol. 2000; 183 925-929
62 Pattinson R C, Makin J D, Funk M et al.. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre, double-blind, placebo-controlled, randomized trial. Dexiprom Study Group. S Afr Med J. 1999; 89 865-870
63 Harding J E, Pang J-M, Knight D B, Liggins G C. Do antenatal corticosteroids help in the setting of preterm rupture of membranes?. Am J Obstet Gynecol. 2001; 184 131-139
64 Liggins G C, Howie R N. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972; 50 515-525
65 Banks B A, Cnaan A, Morgan M A et al.. Multiple courses of antenatal corticosteroids and outcome of premature neonates. Am J Obstet Gynecol. 1999; 181 709-717
66 Thorp J A, Jone A M, Hunt C, Clark R. The effect of multidose antenatal betamethasone on maternal and infant outcomes. Am J Obstet Gynecol. 2001; 184 196-202
67 Lee M-J, Davies J, Guinn D et al.. Single versus weekly courses of antenatal corticosteroids in preterm premature rupture of membranes. Obstet Gynecol. 2004; 103 274-281
68 Simchen M J, Alkazaleh F, Adamson S L et al.. The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction. Am J Obstet Gynecol. 2004; 190 296-304
69 Christensen K K, Ingemarsson I, Leideman T, Solum T, Svenningsen N. Effect of ritodrine on labor after premature rupture of the membranes. Obstet Gynecol. 1980; 55 187-190
70 Levy D L, Warsof S L. Oral ritodrine and preterm premature rupture of membranes. Obstet Gynecol. 1985; 66 621-623
71 Wapner for the NICHD MFMU Network . A randomized trial of single vs weekly courses of corticosteroids. Am J Obstet Gynecol. 2003; 189 S56
72 Guinn D A, Atkinson M W, Sullivan L et al.. Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery: a randomized controlled trial. JAMA. 2001; 286 1581-1587
73 National Institutes of Health (NIH) Consensus Statement . Antenatal corticosteroids revisited: repeat courses. NIH Consens Statement. 2000; 17 1-18
74 Matsuda Y, Ikenoue T, Hokanishi H. Premature rupture of the membranes-aggressive versus conservative approach: effect of tocolytic and antibiotic therapy. Gynecol Obstet Invest. 1993; 36 102-107
75 Mercer B, Moretti M, Rogers R, Sibai B. Antibiotic prophylaxis in preterm premature rupture of membranes: prospective randomized double-blind trial of 220 patients. Am J Obstet Gynecol. 1992; 166 794-802
76 American College of Obstetricians and Gynecologists . ACOG practice bulletin number 47, October 2003: Prophylactic antibiotics in labor and delivery. Obstet Gynecol. 2003; 102 875-882
77 Andrews W W, Goldenberg R L, Hauth J C. Preterm labor: emerging role of genital tract infections. Infect Agents Dis. 1995; 4 196-211
78 Goldenberg R L, Hauth J C, Andrews W W. Intrauterine infection and preterm delivery. N Engl J Med. 2000; 342 1500-1507
79 Yoon B H, Romero R, Yang S H et al.. Interleukin-6 concentrations in umbilical cord plasma are elevated in neonates with white matter lesions associated with periventricular leukomalacia. Am J Obstet Gynecol. 1996; 174 1433-1440
80 Jobe A H, Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev. 1998; 53 81-94
81 American College of Obstetricians and Gynecologists . ACOG committee opinion number 279, December 2002: prevention of early-onset group B streptococcal disease in newborns. Obstet Gynecol. 2002; 100 1405-1412
82 Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC. MMWR Recomm Rep. 2002; 51 1-22
83 Matteson J J, Ramsey P S, Brumfield C G, Carlo W. Preterm premature rupture of membranes: is there an optimal delivery gestational age?. Obstet Gynecol. 2002; 99 74S-75S

Kirk D RaminM.D.

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Minnesota

420 Delaware Street SE, Minneapolis, MN 55455